article Open AccessTop 1% cited

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

New England Journal of Medicine · 2009 · Vol. 361(12) · pp. 1139–1151

Stuart J. Connolly✉(McMaster University)Michael D. Ezekowitz(Lankenau Institute for Medical Research)Salim Yusuf(Hamilton Health Sciences)John W. Eikelboom(Hamilton Health Sciences)Jonas OldgrenAmit Parekh(Lankenau Institute for Medical Research)Janice Pogue(McMaster University)Paul Reilly(Boehringer Ingelheim (United States))Ellison Themeles(Hamilton Health Sciences)Jeanne Varrone(Boehringer Ingelheim (United States))Susan Wang(Boehringer Ingelheim (United States))Marco Alings(Utrecht University)Denis Xavier(St. John's National Academy of Health Sciences)Jun Zhu(Fu Wai Hospital)Rafael Díaz(Estudios Clínicos Latinoamérica)Basil S. Lewis(Carmel Medical Center)Harald Darius(Vivantes Klinikum)Hans‐Christoph Diener(University of Duisburg-Essen)Campbell Joyner(Sunnybrook Health Science Centre)Lars Wallentin

View via DOI Full-text PDF

Abstract

In patients with atrial fibrillation, dabigatran given at a dose of 110 mg was associated with rates of stroke and systemic embolism that were similar to those associated with warfarin, as well as lower rates of major hemorrhage. Dabigatran administered at a dose of 150 mg, as compared with warfarin, was associated with lower rates of stroke and systemic embolism but similar rates of major hemorrhage. (ClinicalTrials.gov number, NCT00262600.)

Atrial Fibrillation Management and Outcomes Cardiac Arrhythmias and Treatments Vitamin K Research StudiesDabigatranMedicineWarfarinAtrial fibrillationStroke (engine)Confidence intervalAnesthesiaInternal medicineRelative riskDirect thrombin inhibitor

MeSH terms

DabigatranAgedAnticoagulantsAtrial FibrillationBenzimidazolesDouble-Blind MethodDyspepsiaEmbolismFemaleFollow-Up StudiesHemorrhageHumansLiverMaleMiddle Aged